US 12,403,190 B2
Coronavirus vaccine and methods of use thereof
Davinder Gill, Andover, MA (US)
Filed by Davinder Gill, Andover, MA (US)
Filed on Jun. 8, 2021, as Appl. No. 17/341,928.
Claims priority of provisional application 63/037,367, filed on Jun. 10, 2020.
Prior Publication US 2021/0393769 A1, Dec. 23, 2021
Int. Cl. A61K 39/215 (2006.01); A61P 31/14 (2006.01); C12N 7/00 (2006.01); A61K 39/00 (2006.01)
CPC A61K 39/215 (2013.01) [A61P 31/14 (2018.01); C12N 7/00 (2013.01); A61K 2039/5258 (2013.01); C12N 2730/10123 (2013.01); C12N 2730/10134 (2013.01); C12N 2770/20023 (2013.01); C12N 2770/20034 (2013.01)] 3 Claims
OG exemplary drawing
 
1. An immunogenic composition comprising a virus-like particle (VLP) and at least one antigenic polypeptide displayed on the surface of the VLP, wherein the at least one antigenic polypeptide is derived from one or more domains of a coronavirus spike(S) protein, a coronavirus membrane (M) protein or combinations thereof, wherein the VLP has at least 95% sequence identity to SEQ ID NO: 167.